CN107149608A - Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared - Google Patents
Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared Download PDFInfo
- Publication number
- CN107149608A CN107149608A CN201710274417.0A CN201710274417A CN107149608A CN 107149608 A CN107149608 A CN 107149608A CN 201710274417 A CN201710274417 A CN 201710274417A CN 107149608 A CN107149608 A CN 107149608A
- Authority
- CN
- China
- Prior art keywords
- kaempferia galamga
- application
- prevention
- glycosides
- galamga glycosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to new opplication of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared.The present invention has been found by experiment that kaempferia galamga glycosides can suppress PECTORAL LIMB SKELETON differentiation and promote fat cell sugar to absorb, and is likely to become treatment diabetes B, a kind of fat new compound, i.e., it has potential effect that is hypoglycemic, improving insulin resistance.Therefore, it is used as preparing prevention and treatment metabolic syndrome medicine and/or health products, especially prevents and improve diabetes medicament, obesity drug.
Description
Technical field
The invention belongs to medicine and/or health product technology field, and in particular to a kind of kaempferia galamga glycosides is preparing prevention and treatment
New opplication in terms of metabolic syndrome medicine.
Background technology
Kaempferia galamga glycosides, is a kind of known native compound, with hypoglycemic, antifatigue, clearing heat and detoxicating, swelling and pain relieving work
With extraction separation is obtained more from plant.Such as：Chinese patent CN201210382447.0 discloses one kind from prunus cerasifera leaf
The method for extracting kaempferia galamga glycosides.
Obesity is that body fat caused by many factors such as heredity, environment accumulates the excessive, chronic metabolic of increased weight
Property disease.It is closely related with diabetes B, dyslipidemia.The energy that the energy of intake exceedes consumption can cause the accumulation of fat.
The increase of adipose tissue is caused with volume increase by increasing for adipocyte number.The propagation of adipose tissue, differentiation are not normal
The accumulation of adipose tissue can be caused.Body fat tissue, which is excessively accumulated, can secrete a series of hormone and Adipocyte Factor interference
Insulin signal transduction in the cell, triggers insulin resistance, and insulin resistance refers to internal peripheral tissues（Muscle, fat）It is right
The sensitiveness reduction of insulin so that intake of the peripheral tissues to glucose is reduced, causes blood glucose rise, and then induce 2 types sugar
Urine disease.Also, insulin resistance runs through the whole process of diabetes B.The primary structure of adipose tissue is sweet in fat drips, fat drips
The content of oily three esters accounts for 95%.Triglycerides is decomposed into free fatty and glycerine in the presence of lipase, and lipolytic is most main
The effect wanted is energy supply.Fat drips are referred to as " energy converter " again, are increased to fat related subcellular structure, intracellular fat drips
Fat cell volume can be caused to increase greatly.Fat Basic of Biology is：The increase of intracellular fat drips cause cell volume increase and
Newborn adipocyte number increases.Therefore, the formation of research fat drips and the metabolism of triglycerides are likely to become solution problem of obesity
One of means.Fat cell originates from mesodermal stem cell, and its differentiation and development goes through several stages：Versatile stem cell,
Mesenchymal precursor, PECTORAL LIMB SKELETON, mature fat cell.3T3-L1 PECTORAL LIMB SKELETONs are thin from mouse embryo fibroblast
Born of the same parents, turn into pre-adipose cell lines through clonal expansion, energy directed differentiation is mature fat cell, is fully shown in the spy of body cell
Point, including morphologic change, the expression of a variety of lipid metabolism enzymes, extensive lipid accumulation etc., it is in vitro study fat cell
Ideal model.The incidence of disease of obesity and diabetes B constantly rises, it has also become global health problem.Exploitation is prevented and treated
The natural products meaning for treating obesity and diabetes B is particularly far-reaching.
The content of the invention
Present invention aims to overcome that prior art defect is preparing prevention and treatment metabolism there is provided a kind of kaempferia galamga glycosides
New opplication in terms of syndrome medicine.
To achieve the above object, the present invention is adopted the following technical scheme that：
New opplication of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared.
Above-mentioned application, can be specifically：Application of the kaempferia galamga glycosides in terms of prevention and treatment diabetes medicament is prepared, especially
It is the application in terms of the medicine and/or health products that promote fat cell sugar absorption.
Above-mentioned application, specifically can also be：Application of the kaempferia galamga glycosides in terms of preparing prevention and improving obesity drug,
There is potential effect of weight reducing, especially answering in terms of the medicine and/or health products that prepare suppression PECTORAL LIMB SKELETON differentiation
With.
Compared to the prior art, the present invention be found by experiment that kaempferia galamga glycosides can suppress PECTORAL LIMB SKELETON differentiation and
Promote fat cell sugar to absorb and improve insulin resistance, be likely to become treatment diabetes B, a kind of fat novel compounds
Thing, i.e., it is with potential effect that is hypoglycemic, improving insulin resistance.Therefore, it is used as preparing prevention and treatment
Metabolic syndrome medicine and/or health products, especially prevent and improve diabetes medicament, obesity drug.
Brief description of the drawings
Fig. 1 is oil red O stain result of the test, in figure, and top is that control group oil red breaks up aspect graph, and bottom is kaempferia galamga glycosides
Oil red differential stain figure；
Fig. 2 is compound kaempferia galamga glycosides to the sugared absorption of 3T3-L1 mature fat cells.
Embodiment
Technical scheme is further discussed in detail with reference to embodiments, but protection scope of the present invention
It is not limited thereto.
Kaempferia galamga glycosides is a kind of known native compound, and extracting separation more from plant obtains.In the present invention kaempferia galamga glycosides from
Plant Ligustrum japonicum Thunb.flower（Guiyang City, Guizhou Province Huaxi District wetland park is collected in June, 2015, is reflected by Guizhou University professor Zhang Qianjun
It is set to glossy privet（Ligustrum lucidumAit.）Flower）Middle extract obtains.Specific extraction separating step is as follows：
1）475 g are taken to dry Ligustrum japonicum Thunb.flower, addition petroleum ether is to Ligustrum japonicum Thunb.flower is submerged, then heating and refluxing extraction 2 times, backflow every time is carried
Take after 2h, refluxing extraction terminate, filtering is residue obtained to volatilize petroleum ether, with Soakage extraction 3 times at room temperature of 70% ethanol（70% second
Alcohol addition is advisable with submerging residue）, each Soakage extraction 3 days, merge extract solution simultaneously concentrate, obtain the total medicinal extract of Ligustrum japonicum Thunb.flower；
2）The total medicinal extract of Ligustrum japonicum Thunb.flower with 50% ethanol dissolve after, with D101 types macroporous resin adsorption separate, successively with water, 20% ethanol,
40% ethanol, 60% ethanol, 95% ethanol gradient elution, each five column volumes of gradient elution, each mL of column volume 2000, elution
After liquid concentration, water position medicinal extract, 20% ethanol position medicinal extract 7g, 40% ethanol position medicinal extract 60g, 60% ethanol position are respectively obtained
Medicinal extract 24g, 95% ethanol position 16g；
3）40% ethanol position medicinal extract（50 g）, separated through 200-300 mesh silica gel column chromatographies, methylene chloride/methanol（V/V,
100:0、50:1、25:1、20:1、15:1、5:1、2:1）Eluted, isolated 2 components.1st component therein（10
g）Column chromatography, methylene chloride/methanol are depressurized by silica gel H（V/V, 10:1、7:1、5:1、3:1、2:1、1:1）Elution, Ran Houjing
Cross the purifying of Sephadex LH-20 gel column chromatographies, methanol elution, isolated compound 1（54 mg）, remaining component continuation
Purified with anti-phase half preparative high-performance liquid chromatographic, use methanol-water（0-40min, the methanol of 40% methanol -100%；40-60min, 100%
Methanol, tR=46min）Elution, isolated compound 2 (71 mg).2nd component therein（5.6 g）Depressurized by silica gel H
Column chromatography and Sephadex LH-20 gel column chromatographies isolate and purify and obtain compound 3（547 mg）.Compound 1, compound 2,
Identified compound 3 is respectively kaempferia galamga glycosides, 10- hydroxyls oleuropein, walking fern element, and concrete structure appraising datum is as follows.
Compound 1：Yellow needles（Methanol）, molecular weight：578, molecular formula：C27H30O14,1H-NMR (DMSO-d6,
400MHz) δ:7.79 (2H, d, J = 8 Hz, H-2′, 6′), 6.92 (2H, d, J = 8 Hz, H-3′, 5′),
6.79 (1H, d, J = 4 Hz, H-8), 6.46 (1H, d, J = 4 Hz , H-6), 5.55 (1H, d, 7-O-
Rha, H-1), 5.30 (1H, d, J = 4 Hz, 3-O-Rha, H-1), 1.13 (3H, d, J = 4 Hz, 7-O-
Rha, H-6), 0.80 (3H, d, J = 8 Hz, 3-O-Rha, H-6). 13C-NMR (DMSO-d6, 100 MHz) δ:
177.97 (C-4), 161.73 (C-7), 160.96 (C-5), 160.26 (C-4′), 157.84 (C-9), 156.14
(C-2), 134.56 (C-3), 130.76 (C-2′, 6′), 120.38 (C-1′), 115.47 (C-3′, 5′),
105.82 (C-10), 101.90 (7-O-Rha, C-1), 99.51 (3-O-Rha, C-1), 98.43 (C-6),
94.63 (C-8), 71.62 (7-O-Rha, C-4), 71.13 (3-O-Rha, C-4), 70.73 (7-O-Rha, C-
3), 70.34 (3-O-Rha, C-3), 70.26 (7-O-Rha, C-2), 70.11 (3-O-Rha, C-2), 70.11
(7-O-Rha, C-5), 69.85 (3-O-Rha, C-5), 17.97 (7-O-Rha, C-6), 17.52 (3-O-Rha,
C-6).Data above and document（Chen Yan, Deng Hongzhu, beam build the southern medical courses in general of research [J] of lespedeza virgata flavones ingredients
College journal, 2008,28 (05):858-860.）Middle compounds Ⅳ is compared, and data are basically identical, therefore authenticating compound 1 is kaempferia galamga
Glycosides.
Compound 2：White solid, molecular weight：556, molecular formula：C25H32O14。1H-NMR (DMSO-d6, 400 MHz)δ:
6.64 (1H, d, J = 8 Hz), 6.60 (1H, s), 6.47 (1H, d, J=8 Hz) for the proton on phenyl ring,
7.53 (1H, s), 6.00 (1H, is t) two alkene Hydrogen Protons, 4.66 (1H, d,J=8Hz) it is glucose end group matter
Son, 3.64 (1H, s, C-11-OCH3)。13C-NMR (DMSO-d6, 100 MHz) δ:170.70 (C-7), 166.15
(C-11), 153.42 (C-3), 145.15 (C-3′), 143.82 (C-4′), 129.24 (C-1′), 128.36 (C-
8), 128.26 (C-9), 119.54 (C-6′), 116.22 (C-2′), 115.59 (C-5′), 107.61 (C-4),
99.14 (Glc-1″), 92.66 (C-1), 77.42 (Glc-3″), 76.63 (Glc-5″), 73.32 (Glc-2″),
69.95 (Glc-4″), 65.16 (C-β), 61.13 (Glc-6″), 57.28 (C-10), 51.34(C-11-OCH3),
39.90 (C-6), 33.71(C-α), 30.69 (C-5).Data above and document（Feng Xuesong, Xu Lei, Gao Huiyuan, Wu Li
The separation of army velvety lilac flower chemical compositions and identification [J] Shenyang Pharmaceutical Universities journal, 2009,26 (09):697-700）In
Compound 5 is compared, and data are basically identical, therefore authenticating compound 2 is 10- hydroxyl oleuropeins.
Compound 3：Yellow powder（Methanol）, molecular weight：594, molecular formula：C27H30O15, 243~246 DEG C of mp,1H-
NMR (DMSO-d6, 400 MHz) δ:8.09 (2H, d, J = 8 Hz, H-2′, 6′), 6.89 (2H, d, J = 8
Hz, H-3′, 5′), 6.83 (1H, s, H-8),6.44 (1H, d, J = 4 Hz , H-6), 5.55 (1H, s,
3-O-Glu, H-1), 5.49 (1H, d, J = 8 Hz, 7-O-Rha, H-1), 1.12 (3H, d, J = 4 Hz,
7-O-Rha, H-6). 13C-NMR (DMSO-d6, 100 MHz) δ:177.70 (C-4), 161.62 (C-7), 160.92
(C-5), 160.17 (C-4′), 156.80 (C-9), 156.03 (C-2), 133.51 (C-3), 130.07 (C-2′,
6′), 120.82 (C-1′), 115.20 (C-3′, 5′), 105.71 (C-10), 100.77 (3-O-Glu, C-1),
99.44 (7-O-Rha, C-1), 98.41 (C-6), 94.54 (C-8), 77.62 (3-O-Glu, C-5), 76.45
(3-O-Glu, C-3), 74.26 (3-O-Glu, C-2), 71.64 (7-O-Rha, C-4), 70.28 (3-O-Glu,
C-4), 70.12 (7-O-Rha, C-3), 69.95 (7-O-Rha, C-2), 69.87 (7-O-Rha, C-5), 60.89
(3-O-Glu, C-6), 17.98 (7-O-Rha, C-6).Data above and document（Yuan Lin, Huang Wenzhong, Liang Deqiang, Ma Yin
Sea, Du Zhizhi close flavonoid glycoside chemical constitution study [J] Chinese Pharmaceutical Journals, 2015,50 (06) in handle clematis:497-
501.）Middle compound 3 is compared, and data are basically identical, therefore authenticating compound 3 is walking fern element（Kaempferol -3-O- β-D- pyrans Portugal
Grape glycosyl -7-O- alpha-L-rhamnosides）.
The influence of application test 1, kaempferia galamga glycosides to 3T3-L1 PECTORAL LIMB SKELETONs activity
Instrument material：Instrument：Preparative high performance liquid chromatography instrument（Waters 2535Q）；Rotary Evaporators（EYELA, Tokyo reason
Change apparatus Co., Ltd.）；LC-3000 efficient liquid phases prepare column chromatography（Beijing Chuangxin Tongheng Science and Technology Co., Ltd.）；Am-400 surpasses
Lead NMR（Bruker）；Electronic balance（Mettler-Toledo companies of the U.S.）；TGL-16gR high speed desktops freeze from
Scheming（Anting Scientific Instrument Factory, Shanghai）；Double one side clean work station（Model：SW-CJ-2FD types producer：Suzhou purification is set
Standby Co., Ltd）；CO2gas incubator（Model：3111 types, producer：Thermo scientific）；Inverted microscope
（Ckx31 types, olympus）；Full temperature shaken cultivation case（The grand experimental facilities Co., Ltd of Nereid in HZP types）；Centrifugation device
（800 type Shanghai Surgical Operation Equipment Factory）；All size liquid-transfering gun（transferpette）；Digital camera（canon EOS450D）
Inverted microscope（Nikon ECLiPSE TS100）；The silica gel thin-layer plates of GF 254（Yantai Hui You silica gel development corporation, Ltd.）；40
~ 80 mesh silica gel, 200 ~ 300 mesh silica gel and silica gel H（Yantai Hui You silica gel development corporation, Ltd.）；Sephadex LH-20（Sweden
Pharmacia companies）；D101 type macroreticular resins（Tianjin sea light Chemical Co., Ltd.）；C-18（German Merk companies）；Remaining examination
Agent is that analysis is pure；Glucose estimation kit（ShangHai RongSheng Biology Pharmacy Co., Ltd, 20161105147）；Glucose mark
Quasi- product（ShangHai RongSheng Biology Pharmacy Co., Ltd, lot number：20161001）；Mouse free fatty acid determination reagent kit（Nanjing is gloomy
Bei Jia bio tech ltd, lot number：201609）；Hyclone（Zhejiang Tian Hang biotech inc, lot number：
20160923）；DMEM high glucose mediums（Beijing Suo Laibao scientific ＆ technical corporation, lot number：F08HV090）；Penicillin streptomycin mixed liquor
（Solarbio, lot number：20161029）；Pancreatin cell dissociation buffer（The green skies, numbering：C0210）；Dimethyl sulfoxide (DMSO)（sigma
SHBC3313V）；Insulin（sigma ）；Tetrazolium bromide（Shanghai Chinese blue Science and Technology Ltd.）；Oil red O（sigma
SLBP5248V）；IBMX（Sigma, BCBH1214V）；DeX（sigma BCBM4557V）.Rosiglitazone tablets（The permanent auspicious pharmacy in Chengdu
Co., Ltd）；Lovastatin capsule（Yangzijiang Pharmaceutical Group Co., Ltd, 20160109）；Cell line：3T3-L1 mice embryonics
Fibroblast is purchased from Chinese Academy of Sciences's cell bank.
Experimental method：
Cell culture is with freezing：
3T3-L1 PECTORAL LIMB SKELETONs, with the DMEM high glucose mediums containing 15% hyclone（Penicillin：10U/mL, the μ of streptomysin 10
g/mL）In 37 DEG C, 5% CO2Cultivated in the CO2gas incubator of saturated humidity, 2 d change liquid once, when cell fusion to 80%
Afterwards, nutrient solution in blake bottle is abandoned, 0.25% trypsin solution 1mL, effect 1min or so is added, 2 times of volume nutrient solutions is added and terminates
Digestion, is blown and beaten attached cell into nutrient solution with piping and druming pipe.Cell suspension is moved into sterile centrifugation tube, 1000 rpm centrifugations 5
Min, abandons supernatant.Passage：The cell precipitation that 1 blake bottle is collected is dispelled with the new nutrient solutions of 1mL, by 1：2 ratios are passed on.Carefully
Born of the same parents freeze：The cell precipitation that 2 blake bottles are collected is with 1.2 mL frozen stock solutions（Hyclone containing 10%DMSO）Dispel to be transferred to and freeze
Pipe is put into program temperature reduction box, is then placed in -80 DEG C of refrigerator overnights, takes out cryopreservation tube and is put into preservation in liquid nitrogen container.
Cytotoxicity assay：
The 3T3-L1 PECTORAL LIMB SKELETONs of exponential phase are collected, concentration of cell suspension are adjusted, with every hole 2 × 105Density inoculation
In 96 well culture plates, 100 μ L cell suspensions are added per hole.Cell is placed in 37 DEG C, 5% CO2And the carbon dioxide of saturated humidity
24 h are cultivated in incubator, cell fusion are treated to 60%-70%, the medicine of concentration gradient is added, each plate sets Normal group, molten
Matchmaker's control group（0.1% DMSO）, administration group, if 6 multiple holes, continue cultivate 48 h after, per hole add 10 μ L MTT solution（5
g/L）, continue to cultivate 4 h.Nutrient solution in hole carefully is sucked, 100 μ L DMSO are added per hole and put concussion and cultivate case（100 r/
min）10 min of middle concussion, make crystal fully dissolve.The absorbance in each hole is measured at the nm wavelength of ELIASA 570（OD
Value）.
Table 1：Influence of the kaempferia galamga glycosides to 3T3-L1 PECTORAL LIMB SKELETON cytotoxic activities（n=6）
As shown in Table 1, Normal group is compared with vehicle control group absorbance, and difference is not statistically significant, and illustrates solvent
Influence is not produced on cell viability.300 μM of dosage group absorbances of kaempferia galamga glycosides are less than Normal group, and difference has statistics meaning
Justice（P<0.05）.Kaempferia galamga glycosides 100,33 and 11 μM of dosage groups are compared with Normal group absorbance, and difference does not have statistics meaning
Justice, illustrates that kaempferia galamga glycosides has CDCC in 300 μM of dosage.I.e.：Kaempferia galamga glycosides can be set to below 100 μM of dosage ranges
Dosage.
The influence that application test 2, kaempferia galamga glycosides break up to 3T3-L1 PECTORAL LIMB SKELETONs
Using 3T3-L1 PECTORAL LIMB SKELETONs as cell model, kaempferia galamga glycosides, oil red O stain identification 3T3- are added in induction atomization
L1 PECTORAL LIMB SKELETON differentiation degrees.
Take the logarithm the 3T3-L1 PECTORAL LIMB SKELETON Secondary Cultures in growth period, by 1.5 × 105Density be inoculated into 96 orifice plates
In, after cell fusion completely, then the h of contact inhibition 48 changes A containing differentiating inducer（0.5 mM IBMX 、1 μM DeX、10
μg/mL Insulin）The high sugared nutrient solutions of DMEM（Containing 15% hyclone）, while dosing（It is divided into blank group, model group, Lip river are cut down
Statin group（50 μM）, administration group）.Change differentiation-inducing agents B after 3 d into（Contain 10 μ g/mL Insulin）The high sugar trainings of DMEM
Nutrient solution（Containing 15% hyclone）, cellar culture liquid is changed after 2 d, liquid is hereafter changed every other day, is cultivated to 12 d, is carefully absorbed nutrient solution,
Ice-cold PBS is washed 2 times, is dried, and the paraformaldehydes of 50 μ L 4% are added per hole and fix 40 min, PBS is washed 2 times, dried again, oil red is added
O dyes 30 min, and PBS is washed 2 times, and ultrapure to wash 2 times, digital camera is taken pictures under inverted microscope（100×）.100 are added per hole
After μ L isopropanols, 40 min absorbance is determined using ELIASA under 495 nm wavelength.As a result it is as follows.
Data processing：As a result represented using mean value ± SD values, data statistics is using SPSS19.0 software single factor tests variance point
Analysis method（One-Way ANOVA）Compare its significant difference.
Table 2：The influence that kaempferia galamga glycosides breaks up to 3T3-L1 PECTORAL LIMB SKELETONs（n=6）
From Fig. 1, table 2, compared with model group, Lovastatin group and 100 μM of dosage group oil red dye levels of kaempferia galamga glycosides are notable
Reduction（P<0.05）, the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs can be suppressed by illustrating 100 μM of mountain naphthalene glycosides, and illustrating that kaempferia galamga glycosides has is used for
Prevention and the potential quality for improving obesity.
The influence that application test 3, kaempferia galamga glycosides absorb to 3T3-L1 mature fat cells sugar
Take the logarithm the 3T3-L1 PECTORAL LIMB SKELETON Secondary Cultures in growth period, by 1.5 × 105Density be inoculated into 96 orifice plates, carefully
After born of the same parents' fusion completely, then the h of contact inhibition 48 changes A containing differentiating inducer（0.5 mM IBMX 、1 μM DeX、10 μg/
mL Insulin）The high sugared nutrient solutions of DMEM（Containing 15% hyclone）, differentiation-inducing agents B is changed into after 3 d（10 μg/mL
Insulin）The high sugared nutrient solutions of DMEM（Containing 15% hyclone）, the high sugared nutrient solutions of the DMEM containing 15% hyclone are changed after 2 d,
Hereafter liquid is changed every other day, is cultivated to 12 d, is induced to differentiate into mature fat cell.Mature fat cell packet, dosing（It is divided into blank
Group, Rosiglitazone group（9.52 μM）, administration group）, continue to cultivate 48 h, take nutrient solution supernatant to be examined by Glucose estimation kit
Survey glucose content in nutrient solution.
Fig. 2 is compound mountain naphthalene glycosides to the sugared absorption of 3T3-L1 mature fat cells.As shown in Figure 2, Rosiglitazone group
Glucose content be less than blank group, difference has statistical significance（P<0.001）.100th, 33, the glucose of 4 μM of mountain naphthalene glycosides groups
Content is less than blank group, and difference has statistical significance（P<0.01）.Illustrate Rosiglitazone, 100,33 and 4 μM of equal energy of mountain naphthalene glycosides
Promote intake of the fat cell to periphery glucose, cause glucose content reduction degree in culture medium to be more than blank group glucose
Content reduces degree, illustrates that it has the potential quality of prevention and treatment diabetes.
Conclusion：Kaempferia galamga glycosides can suppress the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs, and illustrating that it has is used to preventing and improving fertilizer
The potential quality of fat disease；Kaempferia galamga glycosides can also promote intake and absorption of the fat cell to periphery glucose, cause glucose in culture medium
Content reduction degree, which is more than blank group glucose content, reduces degree, illustrates that it has the potential quality of prevention and treatment diabetes.It is comprehensive
For conjunction, kaempferia galamga glycosides can be used for preparing prevention and treatment metabolic syndrome medicine.
Claims (5)
1. application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared.
2. application as claimed in claim 1, it is characterised in that the kaempferia galamga glycosides is preparing prevention and treatment Rezulin object space
The application in face.
3. application as claimed in claim 2, it is characterised in that the kaempferia galamga glycosides is preparing the medicine that promotion fat cell sugar absorbs
Application in terms of thing and/or health products.
4. application as claimed in claim 1, it is characterised in that the kaempferia galamga glycosides is preparing prevention and improving obesity drug side
The application in face.
5. application as claimed in claim 4, it is characterised in that the kaempferia galamga glycosides suppresses the medicine of PECTORAL LIMB SKELETON differentiation preparing
Application in terms of thing and/or health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710274417.0A CN107149608A (en) | 2017-04-25 | 2017-04-25 | Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710274417.0A CN107149608A (en) | 2017-04-25 | 2017-04-25 | Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107149608A true CN107149608A (en) | 2017-09-12 |
Family
ID=59792940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710274417.0A Pending CN107149608A (en) | 2017-04-25 | 2017-04-25 | Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107149608A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112358516A (en) * | 2020-05-30 | 2021-02-12 | 中国农业科学院作物科学研究所 | Application of diosmetin (4-O-methyl) glucoside compound in preparation of lipid-lowering drugs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005306836A (en) * | 2004-03-23 | 2005-11-04 | Seibutsu Yuki Kagaku Kenkyusho:Kk | alpha-AMYLASE INHIBITOR |
| CN102875619A (en) * | 2012-10-09 | 2013-01-16 | 武汉工业学院 | Method for extracting kaempferitrin from prunus cerasifera leaves |
-
2017
- 2017-04-25 CN CN201710274417.0A patent/CN107149608A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005306836A (en) * | 2004-03-23 | 2005-11-04 | Seibutsu Yuki Kagaku Kenkyusho:Kk | alpha-AMYLASE INHIBITOR |
| CN102875619A (en) * | 2012-10-09 | 2013-01-16 | 武汉工业学院 | Method for extracting kaempferitrin from prunus cerasifera leaves |
Non-Patent Citations (1)
| Title |
|---|
| YEW-MIN TZENG, ET AL.: "Kaempferitrin activates the insulin signaling pathway and stimulates secretion of adiponectin in 3T3-L1 adipocytes", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112358516A (en) * | 2020-05-30 | 2021-02-12 | 中国农业科学院作物科学研究所 | Application of diosmetin (4-O-methyl) glucoside compound in preparation of lipid-lowering drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103508919B (en) | Alkaloid compound and preparing the purposes in anticomplement medicament | |
| Qiu et al. | Kaempferol separated from Camellia oleifera meal by high-speed countercurrent chromatography for antibacterial application | |
| CN107028964A (en) | Application of the O α L rhamnosides of Kaempferol 7 in terms of prevention and treatment metabolic syndrome medicine is prepared | |
| CN102485237B (en) | Sweet wormwood herb brewed liquid, and brewing technology thereof | |
| CN108640968B (en) | Mixed-source terpenoid and application thereof in preparation of anti-inflammatory drugs | |
| CN107149608A (en) | Application of the kaempferia galamga glycosides in terms of prevention and treatment metabolic syndrome medicine is prepared | |
| CN106008485A (en) | Medicinal composition of glimepiride, and application thereof in biomedicines | |
| CN104447717B (en) | Demethyl derivative of Herba Silybi mariani flavone lignanoid and preparation method thereof and its purposes | |
| CN101347424A (en) | Use of luteolin in preparing anticomplement medicament | |
| JP5728576B2 (en) | Novel fusaricetin compounds and uses thereof | |
| CN103301179B (en) | Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist | |
| Meyre-Silva et al. | Phytochemical and pharmacological analysis of Bauhinia microstachya (Raddi) Macbr.(Leguminosae) | |
| CN107028963A (en) | Application of the 10 hydroxyl oleuropeins in terms of prevention and treatment diabetes medicament is prepared | |
| CN101239093A (en) | Active component in albizia julibrissin with inhibiting angiogenesis function and preparation method and application thereof | |
| CN105837592B (en) | Phloroglucin a pair of horses going side by side abietane diterpene-kind compound and preparation method thereof and medicinal usage | |
| Zhang et al. | A new flavan-3-ol lactone and other constituents from Euonymus alatus with inhibitory activities on α-glucosidase and differentiation of 3T3-L1 cells | |
| CN107137414A (en) | Cross mountain faint element prepare prevention and improve obesity drug in terms of application | |
| CN104987319B (en) | Marine fungus-derived depside compounds and application thereof in treatment of type 2 diabetes | |
| CN102670674A (en) | Geranium strictipes R. Knuth effective part extract as well as preparation method and drug application | |
| CN103242348B (en) | Indoline diketopiperazines spirocyclic compound and its production and use | |
| CN101358208A (en) | Novel glycoside hydrolase inhibitor preparation method | |
| CN107184658A (en) | Glossy privet flower extract, extracting method and its application in terms of prevention and treatment metabolic syndrome medicine is prepared | |
| CN106565811B (en) | The extracting method of the hypoglycemic active ingredient of Chinese yam aerial part and application | |
| CN102050862B (en) | New honeysuckle chlorogenic acid ester saponin as well as preparation method and use thereof | |
| CN102838570B (en) | Mailuoning ester and preparation method and function thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170912 |